INmune Bio (NASDAQ:INMB) Stock Rating Upgraded by Zacks Investment Research

Zacks Investment Research upgraded shares of INmune Bio (NASDAQ:INMBGet Rating) from a hold rating to a buy rating in a report published on Friday, Zacks.com reports. Zacks Investment Research currently has $7.50 price objective on the stock.

According to Zacks, “INmune Bio Inc. is a clinical-stage biotechnology company. It engages in developing therapies targeting the innate immune system in cancer. The company’s product platform consists of INKmune and INB03. INKmune is a natural killer cell therapeutic which primes the patient’s NK cells to attack developing disease. INB03 inhibits myeloid derived suppressor cells which often cause resistance to immunotherapy, such as anti-PD1 checkpoint inhibitors. INmune Bio Inc. is based in La Jolla, United States. “

Several other analysts also recently commented on INMB. Maxim Group began coverage on shares of INmune Bio in a report on Friday, May 6th. They set a buy rating and a $22.00 target price on the stock. B. Riley restated a buy rating on shares of INmune Bio in a report on Wednesday.

Shares of NASDAQ:INMB opened at $7.09 on Friday. The firm’s 50 day simple moving average is $7.71 and its 200 day simple moving average is $9.98. The company has a current ratio of 23.89, a quick ratio of 23.89 and a debt-to-equity ratio of 0.19. INmune Bio has a fifty-two week low of $6.18 and a fifty-two week high of $30.37.

INmune Bio (NASDAQ:INMBGet Rating) last announced its quarterly earnings results on Thursday, May 5th. The company reported ($0.39) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.21. During the same quarter last year, the company earned ($0.32) earnings per share. Sell-side analysts predict that INmune Bio will post -2.02 EPS for the current year.

Several hedge funds and other institutional investors have recently bought and sold shares of INMB. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in shares of INmune Bio in the third quarter valued at approximately $31,000. Morgan Stanley raised its holdings in shares of INmune Bio by 97.4% in the first quarter. Morgan Stanley now owns 3,093 shares of the company’s stock valued at $37,000 after purchasing an additional 1,526 shares during the last quarter. Bank of America Corp DE raised its holdings in shares of INmune Bio by 109.5% in the fourth quarter. Bank of America Corp DE now owns 3,769 shares of the company’s stock valued at $38,000 after purchasing an additional 1,970 shares during the last quarter. Westside Investment Management Inc. acquired a new stake in shares of INmune Bio in the fourth quarter valued at approximately $79,000. Finally, Wells Fargo & Company MN raised its holdings in shares of INmune Bio by 338.1% in the fourth quarter. Wells Fargo & Company MN now owns 11,509 shares of the company’s stock valued at $118,000 after purchasing an additional 8,882 shares during the last quarter. Institutional investors own 13.91% of the company’s stock.

INmune Bio Company Profile (Get Rating)

INmune Bio, Inc, a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03, an immunotherapy that treats patients with hematologic malignancies and solid tumors; and XPro1595 for the treatment of Alzheimer's disease.

Featured Stories

Get a free copy of the Zacks research report on INmune Bio (INMB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for INmune Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INmune Bio and related companies with MarketBeat.com's FREE daily email newsletter.